REGN241206P550000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
RBC Capital Remains a Buy on Regeneron (REGN)
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy
Sanofi (SNY.US)/Regeneron (REGN.US) Dupilumab Injection approved again for clinical treatment of pure moss disease in China
A new clinical trial implied consent has been granted for the duperimabd injection declared by Sanofi (SNY.US).
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Regeneron Pharmaceuticals Unusual Options Activity
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock?
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
S&P 500, Dow Hit Records Right After Open | Live Stock
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?
Citi Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $895
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,110
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 15% CAGR Over the Last Five Years
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters